Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 0.41 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | RAF1 | P04049 | 4/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | STK16 | O75716 | 1/20 | 0.37 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384170 | 0.90 | BRAF (0.53) | FGFR1BRAFRAF1DDR2BTK | |
| SCHEMBL3384533 | 0.78 | BRAF (0.54) | FGFR1BRAFRAF1DDR2AAK1 | |
| SCHEMBL3386050 | 0.75 | DDR2 (0.54) | FGFR1BRAFDDR2DYRK1A | |
| SCHEMBL3384692 | 0.73 | BRAF (0.54) | FGFR1BRAFRAF1DDR2DYRK1A | |
| SCHEMBL3384315 | 0.72 | BRAF (0.64) | FGFR1BRAFRAF1DDR2BTK | |
| SCHEMBL3384708 | 0.72 | MEN1 (0.51) | FGFR1AAK1FGFR2FGFR3KDM4E | |
| SCHEMBL8738811 | 0.72 | KDR (0.42) | FGFR1AAK1FGFR2DYRK1AKDM4E | |
| SCHEMBL3384920 | 0.71 | USP2 (0.51) | FGFR1AAK1FGFR2FGFR3KDM4E | |
| SCHEMBL3387717 | 0.69 | KDM4E (0.47) | FGFR1FGFR2FGFR3KDM4E | |
| SCHEMBL3386722 | 0.69 | RAF1 (0.53) | BRAFRAF1AAK1DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130069-A1 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | RAF1, RET, KDR | FGFR1 9/4885BRAF 5/4885RAF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.